News
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.
Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...
The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
2d
Zacks Investment Research on MSNModerna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspikeModerna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...
20h
Global News - Inquirer.net on MSNCOVID jabs safe despite US alertA vaccine expert assured Filipinos on Wednesday that all vaccines are safe after the United States Food and Drug ...
Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the pharmaceutical company expands its ...
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results